Literature DB >> 9884837

In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: effect of concentration and exposure time.

E J Ernst1, M E Klepser, M A Pfaller.   

Abstract

This study investigated the potential antagonism of fluconazole on amphotericin B activity against Candida albicans when administered sequentially in vitro. Yeast cells were exposed to fluconazole for time periods ranging from 0 to 24 h before the addition of amphotericin B. The combination showed fungicidal (> or = 3 log 10 reduction in CFU/mL) activity. After 4 h of exposure to fluconazole, amphotericin B activity was partially inhibited at the lower concentration tested (0.25 x MIC). Amphotericin B activity was dramatically decreased by previous exposure to fluconazole for greater than or equal to 8 h at both the high and low concentrations tested. The activity of amphotericin B against yeast exposed to fluconazole for at least 8 h was indistinguishable from fluconazole alone and was fungistatic (< or = 2 log 10 reduction in CFU/mL). This inhibition of amphotericin B activity persisted for a very short period (< 6 h) after removal of fluconazole from the culture medium, indicating the need for continued exposure to fluconazole for lasting inhibition of amphotericin B activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9884837     DOI: 10.1016/s0732-8893(98)00099-6

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  11 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Voriconazole-induced inhibition of the fungicidal activity of amphotericin B in Candida strains with reduced susceptibility to voriconazole: an effect not predicted by the MIC value alone.

Authors:  Anders Lignell; Elisabeth Löwdin; Otto Cars; Dominique Sanglard; Jan Sjölin
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect.

Authors:  S M Gunderson; H Hoffman; E J Ernst; M A Pfaller; M E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  Use of Antifungal Combination Therapy: Agents, Order, and Timing.

Authors:  Melissa D Johnson; John R Perfect
Journal:  Curr Fungal Infect Rep       Date:  2010-05-01

Review 5.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

6.  In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis.

Authors:  Yabin Zhou; Ganggang Wang; Yutang Li; Yang Liu; Yu Song; Wenshuai Zheng; Ning Zhang; Xiaoyan Hu; Shikun Yan; Jihui Jia
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

7.  Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods.

Authors:  Erika J Ernst; Keiko Yodoi; Ellen E Roling; Michael E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 8.  Antifungal pharmacokinetics and pharmacodynamics.

Authors:  Alexander J Lepak; David R Andes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

Review 9.  Antifungal combination therapy: clinical potential.

Authors:  John W Baddley; Peter G Pappas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

10.  In vitro antimicrobial activity of a novel compound, Mul-1867, against clinically important bacteria.

Authors:  George Tetz; Victor Tetz
Journal:  Antimicrob Resist Infect Control       Date:  2015-11-06       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.